Delcath Systems Files 8-K on Operations and Financials
Ticker: DCTH · Form: 8-K · Filed: Oct 20, 2025 · CIK: 872912
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
DELCATH filed an 8-K on Oct 18th covering operations and financials. Check it out.
AI Summary
Delcath Systems, Inc. filed an 8-K on October 20, 2025, reporting on events that occurred on October 18, 2025. The filing pertains to results of operations, financial condition, and other events, including financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Queensbury, NY.
Why It Matters
This 8-K filing provides an update on Delcath Systems' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- DELCATH SYSTEMS, INC. (company) — Registrant
- October 18, 2025 (date) — Earliest event reported
- October 20, 2025 (date) — Date of report filing
- Delaware (jurisdiction) — State of incorporation
- Queensbury, NY (location) — Principal executive offices
FAQ
What specific events are detailed in the 'Results of Operations and Financial Condition' section of this 8-K?
The filing indicates it covers results of operations and financial condition, but the specific details are not provided in the provided text. The full filing would contain this information.
What is the significance of the 'Regulation FD Disclosure' item listed?
This indicates that the company is making public disclosures to prevent selective disclosure of material nonpublic information, ensuring all investors receive information simultaneously.
What type of 'Other Events' are typically reported in an 8-K filing?
Other Events can include a wide range of material events such as executive changes, bankruptcy, or other significant corporate actions not covered by other 8-K items.
What does the inclusion of 'Financial Statements and Exhibits' signify?
This means that the filing includes important financial documents and supporting exhibits that provide a more detailed look at the company's financial health and performance.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 1,765 words · 7 min read · ~6 pages · Grade level 11.4 · Accepted 2025-10-20 06:01:41
Key Financial Figures
- $20.5 million — nd HEPZATO KIT revenue of approximately $20.5 million HEPZATO KIT revenue of $19.2 million
- $19.2 million — $20.5 million HEPZATO KIT revenue of $19.2 million CHEMOSAT revenue of $1.3 million Gr
- $1.3 million — of $19.2 million CHEMOSAT revenue of $1.3 million Gross margins expected to be 87% Ne
- $0.8 million — gins expected to be 87% Net income of $0.8 million Positive adjusted EBITDA of $5.3 mill
- $5.3 million — 8 million Positive adjusted EBITDA of $5.3 million Positive operating cash flow of appro
- $4.8 million — ve operating cash flow of approximately $4.8 million As of September 30, 2025, Delcath had
- $88.9 million — ber 30, 2025, Delcath had approximately $88.9 million of cash, cash equivalents and short-ter
Filing Documents
- d51469d8k.htm (8-K) — 56KB
- d51469dex991.htm (EX-99.1) — 21KB
- d51469dex992.htm (EX-99.2) — 33KB
- g51469g41r30.jpg (GRAPHIC) — 19KB
- 0001193125-25-242909.txt ( ) — 265KB
- dcth-20251018.xsd (EX-101.SCH) — 3KB
- dcth-20251018_lab.xml (EX-101.LAB) — 17KB
- dcth-20251018_pre.xml (EX-101.PRE) — 11KB
- d51469d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Delcath or on its behalf. This Current Report on Form 8-K contains forward-looking statements, including statements regarding Delcath's 2025 full-year revenue guidance, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: Delcath's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; Delcath's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of Delcath and those of its third-party suppliers/manufacturers; Delcath's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; Delcath's ability to obtain reimbursement for the HEPZATO KIT; and Delcath's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact Delcath, please see Delcath's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not poss
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release (Preliminary Financial Results), dated October 18, 2025. 99.2 Press Release (CHOPIN Trial results), dated October 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DELCATH SYSTEMS, INC. Date: October 20, 2025 By: /s/ Gerard Michel Name: Gerard Michel Title: Chief Executive Officer